Last Updated: October 3, 2025
Analyzing Management
Leadership within public companies serves as a crucial swing factor for hedge funds and asset managers during both initial due diligence and ongoing risk assessment. ManagementTrack offers a systematic approach that eliminates distractions—highlighting distinct strengths and weaknesses, identifying red and green flags, and establishing a direct connection between CEO actions and performance outcomes.
CEO Zovighian’s execution & regulatory woes risk growth and investor confidence.
Analysis of Edwards Lifesciences CEO Bernard Zovighian
While possessing some franchise experience, recent forecasting failures, execution concerns, and personal regulatory issues suggest Bernard Zovighian is poorly positioned to navigate critical growth drivers and restore investor confidence.
Management evaluated Bernard Zovighian’s track record and skillset against the following key factors for EW:
- Defending TAVR market share against intensifying competition.
- Managing margin headwinds from spending and acquisitions.
- Securing favorable NCD update to unlock asymptomatic AS market.
- Executing TMTT ramp-up to deliver a second growth engine.
Bernard Zovighian’s Track Record & Key Open Questions to Research
ManagementTrack provides track record analysis, career playbooks, strengths, and weaknesses for every CEO. It allows investors to dig deeper to uncover hard to find data to answer the most pressing questions.
Reach out to sales@paragonintel.com or visit https://paragonintel.com/access-now/ for more information.
Question #1
When faced with a choice between managing bad news to protect the company’s narrative and being fully transparent with investors about operational challenges like the TAVR slowdown, which path does Zovighian’s instinct and track record suggest he will take?
Question #2
As Zovighian drives the high-stakes TMTT ramp-up, will he prioritize aggressive commercial execution to hit growth targets at all costs, or will he demonstrate a more disciplined approach to managing the significant clinical and patient safety risks that have emerged?
Question #3
Given Zovighian’s recent aggressive M&A strategy, will he prove to be a disciplined steward of capital who can integrate these acquisitions to drive profitable growth, or does his recent failure in financial forecasting on the core TAVR business suggest he prioritizes bold strategic moves over rigorous operational and financial oversight?
Why Do Investors Use ManagementTrack?
What is ManagementTrack’s assessment of Bernard Zovighian at EW?
ManagementTrack evaluates an executive’s track record, key strengths, and weaknesses through its proprietary career analysis and interviews with former colleagues. This profile is then measured against the most critical success factors for EW, including the need to defend TAVR market share, manage margin pressures from spending and acquisitions, secure a favorable NCD update to access the asymptomatic AS market, and execute the TMTT ramp-up to establish a second growth engine.
What other methods does ManagementTrack use to link executive behavior to company performance?
ManagementTrack utilizes proprietary models to identify abnormal levels of executive evasion during earnings call Q&A. Its systems also analyze insider transaction data to flag predictive outlier trades. These elements, combined with the ManagementTrack Rating—a predictive 1-10 score assigned to every executive—give investors a clear, forward-looking view on how leadership capabilities will likely affect future performance.
What is the scope of ManagementTrack’s coverage?
ManagementTrack delivers real-time coverage on the C-suite of every publicly traded company.
How to Learn More
Reach out to sales@paragonintel.com or visit https://paragonintel.com/access-now/ to see our deep dive analysis on any executive.
Author
Colby Howard is the co-founder and President of Paragon Intel. Paragon Intel’s ManagementTrack is the premier executive analysis platform for hedge funds, asset managers, corporations, boards, and recruiters. Our proprietary data, built over a decade of analysis, allows us to analyze each public company executive to understand their fit and ability to execute at their company. We leverage our proprietary data – key quantitative research on an executive’s career plus interviews with their former colleagues – with public documents, including SEC filings (10-K, 10-Q), investor presentations, press releases, and earnings call transcripts. to build a holistic, evidence-based view of an executive’s capabilities and playbook.
Sources
- Verified Career History by ManagementTrack for Bernard Zovighian
- Analysis of Capital Allocation, Performance, and Fundamentals across career by ManagementTrack
- Edwards Lifesciences Corp. 10Q
- Edwards Lifesciences Corp. 10K
- Edwards Lifesciences Corp. Earnings Calls
- Edwards Lifesciences Corp. Press Releases
Relevant Links
- For more information on ManagementTrack’s Data visit: https://paragonintel.com/management-track-data/
- For more information on ManagementTrack’s Interview & Analysis visit: https://paragonintel.com/management-track-reports/
- For more information on ManagementTrack’s Interview library visit: https://paragonintel.com/management-track-report-library/
- For more information on ManagementTrack’s Evasion Analysis visit: https://paragonintel.com/earnings-call-evasion/
- For more information on how ManagementTrack helps hedge funds and asset managers visit: https://paragonintel.com/
